EPS for Alimera Sciences, Inc. (ALIM) Expected At $-0.06

October 14, 2018 - By Marie Mckinney

Alimera Sciences, Inc. (NASDAQ:ALIM) LogoInvestors sentiment decreased to 0.93 in 2018 Q2. Its down 0.57, from 1.5 in 2018Q1. It worsened, as 7 investors sold Alimera Sciences, Inc. shares while 8 reduced holdings. 8 funds opened positions while 6 raised stakes. 29.19 million shares or 2.32% more from 28.53 million shares in 2018Q1 were reported.
Armistice Capital Ltd Limited Liability Company accumulated 6.94M shares. Spark Mgmt Ltd Liability stated it has 0% of its portfolio in Alimera Sciences, Inc. (NASDAQ:ALIM). Strs Ohio reported 43,569 shares. Acuta Capital Partners Limited Liability Company has invested 0.17% in Alimera Sciences, Inc. (NASDAQ:ALIM). Renaissance Technology owns 475,000 shares or 0% of their US portfolio. Savings Bank Of Mellon reported 27,227 shares. Weiss Multi invested 0% in Alimera Sciences, Inc. (NASDAQ:ALIM). Jw Asset Mngmt holds 0.26% or 413,300 shares. Prelude Cap Limited has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM). 1.13 million were reported by Morgan Stanley. Pnc Fincl Service Incorporated has 0% invested in Alimera Sciences, Inc. (NASDAQ:ALIM). Shufro Rose And Co Lc invested in 0% or 10,000 shares. Bnp Paribas Arbitrage owns 5 shares for 0% of their portfolio. Vanguard Group reported 2.08M shares or 0% of all its holdings. Signaturefd Ltd Llc reported 1,416 shares or 0% of all its holdings.

Since May 7, 2018, it had 1 buying transaction, and 0 sales for $10,500 activity.

Analysts expect Alimera Sciences, Inc. (NASDAQ:ALIM) to report $-0.06 EPS on November, 7.They anticipate $0.02 EPS change or 50.00 % from last quarter’s $-0.04 EPS. After having $-0.06 EPS previously, Alimera Sciences, Inc.’s analysts see 0.00 % EPS growth. The stock increased 1.50% or $0.0143 during the last trading session, reaching $0.97. About 36,920 shares traded. Alimera Sciences, Inc. (NASDAQ:ALIM) has declined 21.99% since October 14, 2017 and is downtrending. It has underperformed by 37.61% the S&P500.

Alimera Sciences, Inc. (NASDAQ:ALIM) Ratings Coverage

Among 2 analysts covering Alimera (NASDAQ:ALIM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Alimera had 3 analyst reports since May 8, 2018 according to SRatingsIntel. As per Tuesday, June 12, the company rating was maintained by H.C. Wainwright. On Tuesday, May 8 the stock rating was maintained by H.C. Wainwright with “Buy”.

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company has market cap of $67.94 million. It focuses on diseases affecting the back of the eye or retina. It currently has negative earnings. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Alimera Sciences, Inc. (NASDAQ:ALIM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.